Intravesical therapy of bladder cancer: An immunotherapy success story

International Journal of Urology

Volumn 3, Issue 5, 1996, Pages 329-333

  Morales, Alvaro ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Bladder cancer; Immunotherapy

Indexed keywords

BCG VACCINE; BROPIRIMINE; INTERFERON; KEYHOLE LIMPET HEMOCYANIN;

BACTERIAL CELL WALL; BLADDER CANCER; CANCER RECURRENCE; CANCER STAGING; CARCINOMA IN SITU; ENDOSCOPIC SURGERY; FEVER; HUMAN; IMMUNOTHERAPY; INTRAVESICAL DRUG ADMINISTRATION; LACTOBACILLUS CASEI; MYCOBACTERIUM; PRIORITY JOURNAL; PROPHYLAXIS; SEPSIS; SHORT SURVEY; TUBERCULOSIS;

EID: 0029783963     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.1996.tb00548.x     Document Type: Short Survey

References (30)

1. Lamm DL. Carcinoma in situ. Urol Clin North Am 1992;19:499.
2. Vegt PDJ, Witjes JA, Witjes WPJ, et al. Randomized study of intravesical mitomycin C, bacillus Calmette-Guerin, Tice and Bacillus Calmette-Guérin, RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol 1995;153: 929.
3. Morales A, Edinger D, Bruce AW. Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 1976;116:180.
4. Meng MV, Sanda MG. Comparison of intravesical BCG to radical cystectomy for high grade, T1 TCC using Markov decision tree analysis. J Urol 1995; 153:466A.
5. Akaza H, Hinotsu S, Aso Y, Kakizoe T, Koiso K. Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Cancer 1995;75:552.
6. Kurth KH, Schellhammer PF, Okalima E, Akadas A, Jakse G, Herr HW, Calais da Silva F, Fukushima S, Nagayama T. Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra. Int J Urol 1995; 2(suppl 2):8-22.
7. Lamm DL, van der Meijden APM, Akaza H, Brendler ChB, Hedlund PO, Mizutani Y, Ratliff TL, Robinson MRG, Shinka T. Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? Int J Urol 1995;2(suppl 2):23-35.
8. Morales A. Treatment of carcinoma in situ of the bladder with BCG. A phase II study. Cancer Immunol Immunother 1980;9:69.
9. Cookson MS, Sarosdy MF. Management of stage T1 superficial bladder cancer with intravesical BCG therapy. J Urol 1992;148:797.
10. Pansadoro V, Emiliozzi P, Defidio L, Donadio D, Florio A, Maurelli S, Lauretti S, Sternberg CN. Bacillus Calmette-Guérin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long term results. J Urol 1995;154:2054.
11. Ratliff TL, Kavoussi LR, Catalona WJ. Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J Urol 1988;139:410.
12. Ratliff T, Gillen D, Catalona W. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol 1987;137:155.
13. Lamm DL, Meijden APM, Morales A, et al. Incidence and treatment of complications of BCG intravesical therapy for superficial bladder cancer. J Urol 1992;147: 596.
14. Morales A, Nickel JC, Wilson JWL. Dose-response of BCG in the treatment of superficial carcinoma of the bladder. J Urol 1992;147:1256.
15. Pagano F, Bassi P, Piazza N, Abatangelo G, Ferrante GLD, Milani C. Improving the efficacy of BCG immunotherapy by dose reduction. Eur Urol 1995;27 (suppl 1):19.
16. Martinez-Pineiro JA, Flores N, Isorna S. Comparison between standard BCG dose (81 mg) versus a three fold reduced dose (27 mg) in superficial bladder cancer. J Urol 1996;155:493A.
17. Bohle A, Balck F, Wiertsheim VJ, Jocham D.The quality of life during intravesical bacillus Calmette-Guérin therapy. J Urol 1996;155:1221.
18. Lamm DL. Bladder cancer: improving patient selection and treatment. J Urol 1995;153:942.
19. Friedman D, Mooppan UM, Rosen Y, Kim H. The effect of intravesical instillations of thiotepa, mitomycin C and adryamicin in normal urothelium. J Urol 1991;145:1060.
20. Kanamaru H, Saikawa S, Muranaka K, Mori H, Akino H, Miwa Y, Nakamura N, Fujita T, Okada K. Early disease progression after intravesical BCG therapy for superficial bladder cancer. Int J Urol 1996;3:18-22.
21. Glashan AW. A controlled randomized trial of intravesical alpha-2-beta interferon in carcinoma in situ of the bladder. J Urol 1990;144:658.
22. Boccardo F, Cannata D, Rubagotti A, et al. Prophylaxis of superficial bladder cancer with mitomycin or interferon alpha-2-b: results of a multicentric Italian study. J Clin Oncol 1994;12:7.
23. Williams RD, Gleason DM, Smith AY, Zinner N, Sagalowski AI, Montie JE, Brosman SA, Marks LS, Brito G, Boxer BJ, Blank BH, Neri R, Rideen J. Pilot study of intravesical alpha-2b interferon for treatment of bladder carcinoma in situ following BCG failure. J Urol 1996;155:494A.
24. Kalbe T, Mohring K, Ikinger U, et al. Intravesical prevention of recurrence in superficial urinary bladder cancer with BCG and KLH: a prospective randomized study. Urologe 1991;30:118.
25. Lamm DL, Morales A, Grossman HB, Bruce L, Swerdlow R, Habicht K. KLH immunotherapy of papillary and in situ transitional cell carcinoma of the bladder: a multicenter phase I-II clinical trial. J Urol 1996;155:662A.
26. Sasaki H, Schmitt D, Hayashi Y, Pollard B, Suzuki F. Induction of interleukin 3 and tumor resistance by SSM, a cancer immunotherapeutic agent extracted from M. tuberculosis Cancer Res 1990;50:4032.
27. Morales A, Nickel JC, Downey J, et al. Immunotherapy of an experimental adenocarcinoma of the prostate. J Urol 1995;153:1706.
28. Aso K. Lactobacillus casei in the prophylaxis of superficial bladder cancer. Eur Urol 1995;27:104.
29. Riggs DR, DeHaven JI, Lamm DL. Lactobacillus casei immunotherapy of murine bladder cancer (MBT-2). J Urol 1996;155:319.
30. Sarosdy MF, Lamm DL, Williams RD. Phase I trial of oral bropirimine in superficial bladder cancer. J Urol 1992;147:31.